Day: October 29, 2021

SINGAPORE, Oct. 28, 2021 (GLOBE NEWSWIRE) — Ibanera, a global digital banking platform and financial services provider, announced that it will offer fintech services to customers in Singapore with a focus on domestic and cross-border money transfer services.

The company offers a robust suite of compliance programs for transaction monitoring and has partnered with Jumio, Refinitiv and Comply Advantage to assist with KYC/AML management, and transaction monitoring. Ibanera conducts multiple tiers of investigation and cross-checking through advanced document analysis, address validation via Proof of Address together with Geolocation check, forensic analysis, AML/OFAC/PEP and other database screening.

“Growing our presence in Singapore allows us to expand our network in the Southeast Asia region,” said Bjorn Snorrason, General Manager of Ibanera. “Our tailored fintech solutions combined with robust compliance procedures ensure a seamless customer experience.”

Ibanera is a licensed financial institution in the United States, Canada, Europe and Singapore. Ibanera holds a Major Payment Institution license regulated by the Monetary Authority Service under the 2019 Payment Services Act.

About Ibanera

Ibanera is a global digital banking platform and financial services provider. We develop tailored fintech solutions for banks, corporations and entrepreneurs worldwide. We specialize in cross-border payments, currency conversion, mobile banking, and merchant services. Ibanera has leveraged strategic partnerships with ComplyAdvantage and Refinitiv to expand Know Your Customer (KYC) and Anti-Money Laundering (AML) compliance programs. Regulated in the United States, Canada, Europe and Singapore, Ibanera positions itself as a competitive fintech leader with a credible global footprint. For more information, visit ibanera.com.

Contact: Media@ibanera.com

This content was issued through the press release distribution service at Newswire.com.

MAYFIELD, Pa., Oct. 28, 2021 (GLOBE NEWSWIRE) — via InvestorWire — JT Medical (the “Company”), JT Medical announces that it is now accepting memorandums of understanding (MOUs) from researchers wishing to secure high quality, repeatable batch, plant-based medical products derived from regulated plants, including but not limited to, cannabis, psilocybin mushroom, and peyote. These products will be grown in the Company’s U.S. Food and Drug Administration (DEA) licensed facility in Mayfield, Pennsylvania, in the U.S.

JT Medical currently has two MOUs to cultivate medical cannabis and psilocybin mushroom. As supply capacity is limited, subsequent MOUs will be prioritized on a “first-come” basis. Additional capacity will be provided based on the number and size of MOUs that proceed to a definitive agreement.

Scott Noerr, co-founder and CFO of JT Medical, notes, “We anticipate strong interest as many companies are now becoming eligible for research and development (R&D) tax credits.”

Cultivation equipment will be provided by Sprout AI Inc, a publicly traded company (CSE: SPRT) (www.sproutai.solutions). Sprout AI provides self-contained habitats that enable high-quality, repeatable batches, through the control of variables that are known to impact crop duplication. Sprout AI habitats are used to ensure the replication of active medicinal plant ingredients as well as terpene, flavonoids and other desired components. This enables both short-, mid-, and long-term studies are derived from the “same” product for medical research and efficacy reports.

The Sprout AI habitats will be operated using the enterprise resource planning and compliance (ERPc) software provided by One System One Solution (OS2) that will also permit researchers to track their batches from inception from seed, clone, or tissue sample, through to the final use/product. This access will include monitoring data of each batch while in production and tracing each batch through harvest, production and delivery. OS2 has been approved in seven countries for use under medical licensed projects.

Production, process, and distribution of plant-based products will be under license from the U.S. Food and Drug Administration (DEA) to be granted to JT Medical.

About JT Medical

To learn more about JT Medical Visit https://www.jtmedicalgroup.com/.

Co-Founder – CFO
Scott N Noerr
JT Medical, LLC
Phone: 717-437-0437

E-mail: scott@jtmedical.net

About Sprout AI

To learn more about Sprout AI visit https://www.sproutai.solutions.

Investor Relations Contact
Colleen McKay
Sprout AI Inc.
Tel: + 1 (289) 231-9026
E-mail: cmckay@sproutai.solutions

Forward-Looking Statements

This release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended and Section 21E of the Securities Exchange Act of 1934, as amended. All forward-looking statements are inherently uncertain as they are based on current expectations and assumptions concerning future events or future performance of the company. Readers are cautioned not to place undue reliance on these forward-looking statements, which are only predictions and speak only as of the date hereof. In evaluating such statements, prospective investors should review carefully various risks and uncertainties identified in this release and matters set in the company’s SEC filings. These risks and uncertainties could cause the company’s actual results to differ materially from those indicated in the forward-looking statements.

Wire Service Contact
InvestorWire (IW)
Los Angeles, California
www.InvestorWire.com
212.418.1217 Office
Editor@InvestorWire.com